CD86 and Burkitt lymphoma: In summary, CDK4/6 inhibitors are shown here to inhibit proliferation of PEL, KSHV-infected endothelial cells, and EBV+ Burkitt’s lymphoma cells and also to reverse virus-induced suppression of MHC-I, ICAM-1, and B7-2 on these cells.